《歐洲血管外科學會（ESVS）2021 年靜脈血栓管理臨床實踐指南》解讀_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

吳洲鵬 ,  趙紀春 , 馬玉奎

四川大學華西醫院血管外科（成都 610041）;

Corresponding?author：

趙紀春, Email: zhaojc3@126.com

Keywords：

DOI：

10.7507/1007-9424.202101019

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 吳洲鵬, 趙紀春, 馬玉奎. 《歐洲血管外科學會（ESVS）2021 年靜脈血栓管理臨床實踐指南》解讀. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(2): 165-170. doi: 10.7507/1007-9424.202101019 Copy

1.	Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg, 2020: S1078-5884(20)30868-6.
2.	Wanhainen A, Verzini F, Van Herzeele I, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg, 2019, 57(1): 8-93.
3.	Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis, 2016, 41(1): 3-14.
4.	Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis, 2009, 28(4): 401-409.
5.	Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest, 2016, 149(2): 315-352.
6.	Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ, 1998, 316(7124): 17-20.
7.	Ageno W, Camporese G, Riva N, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol, 2015, 2(11): e474-e480.
8.	Karande GY, Hedgire SS, Sanchez Y, et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther, 2016, 6(6): 493-507.
9.	Sampson FC, Goodacre SW, Thomas SM, et al. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol, 2007, 17(1): 175-181.
10.	Dronkers CE, Klok FA, Huisman MV. Current and future perspectives in imaging of venous thromboembolism. J Thromb Haemost, 2016, 14(9): 1696-1710.
11.	Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost, 2003, 89(2): 228-234.
12.	Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 2014, 348: g1340.
13.	Kelly J, Hunt BJ. The utility of pretest probability assessment in patients with clinically suspected venous thromboembolism. J Thromb Haemost, 2003, 1(9): 1888-1896.
14.	Garcia-Fuster MJ, Fabia MJ, Furio E, et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord, 2014, 14: 178.
15.	Zhou M, Zhang L, Ding Y, et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis. Thromb Res, 2017, 157: 147-153.
16.	Klein A, Shepshelovich D, Spectre G, et al. Screening for occult cancer in idiopathic venous thromboembolism—Systemic review and meta-analysis. Eur J Intern Med, 2017, 42: 74-80.
17.	Kleinjan A, van Doormaal FF, Prins MH, et al. Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med, 2012, 70(7): 311-317.
18.	Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis, 2016, 41(1): 154-164.
19.	Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med, 2017, 377(12): 1177-1187.
20.	Garcia-Horton A, Kovacs MJ, Abdulrehman J, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res, 2017, 149: 76-80.
21.	Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis, 2015, 39(3): 367-378.
22.	Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med, 1996, 334(11): 677-681.
23.	Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med, 1996, 334(11): 682-687.
24.	Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev, 2018, (3): CD003076.
25.	Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ, 2011, 342: d3036.
26.	Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost, 2004, 2(5): 743-749.
27.	Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 2001, 103(20): 2453-2460.
28.	Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor’s choice —A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg, 2019, 57(5): 685-701.
29.	Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv, 2018, 2(7): 788-796.
30.	Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368(8): 699-708.
31.	Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med, 2017, 376(13): 1211-1222.
32.	Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012, 367(21): 1979-1987.
33.	Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012, 366(21): 1959-1967.
34.	Shaw JR, Douketis J, Le Gal G, et al. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost, 2019, 17(7): 1171-1178.
35.	Meissner MH. Duplex follow-up of patients with DVT: does it have clinical significance? Semin Vasc Surg, 2001, 14(3): 215-221.
36.	Ascher E, Depippo PS, Hingorani A, et al. Does repeat duplex ultrasound for lower extremity deep vein thrombosis influence patient management? Vasc Endovascular Surg, 2004, 38(6): 525-531.
37.	Schulman S, Granqvist S, Holmstr?m M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med, 1997, 336(6): 393-398.
38.	Kyrle PA. How I treat recurrent deep-vein thrombosis. Blood, 2016, 127(6): 696-702.
39.	Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood, 2017, 129(25): 3285-3293.
40.	Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: A review. Thromb Res, 2018, 164 Suppl 1: S172-S177.
41.	Siragusa S, Malato A, Saccullo G, et al. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. Am J Hematol, 2011, 86(11): 914-917.
42.	Partsch H, Bl?ttler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg, 2000, 32(5): 861-869.
43.	Roumen-Klappe EM, den Heijer M, van Rossum J, et al. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. J Thromb Thrombolysis, 2009, 27(4): 400-405.
44.	Arpaia G, Cimminiello C, Mastrogiacomo O, et al. Efficacy of elastic compression stockings used early or after resolution of the edema on recanalization after deep venous thrombosis: the COM. PRE Trial. Blood Coagul Fibrinolysis, 2007, 18(2): 131-137.
45.	Amin EE, Bistervels IM, Meijer K, et al. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood, 2018, 132(21): 2298-2304.
46.	Kahn SR, Shapiro S, Ducruet T, et al. Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost, 2014, 112(6): 1137-1141.
47.	Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med, 2004, 141(4): 249-256.
48.	Ten Cate-Hoek AJ, Amin EE, Bouman AC, et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol, 2018, 5(1): e25-e33.
49.	Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet, 1997, 349(9054): 759-762.
50.	Aschwanden M, Jeanneret C, Koller MT, et al. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg, 2008, 47(5): 1015-1021.
51.	Ten Cate-Hoek AJ, Bouman AC, Joore MA, et al. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open, 2014, 4(9): e005265.
52.	Mol GC, van de Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ, 2016, 353: i2691.
53.	Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood, 2012, 119(6): 1561-1565.
54.	Turner TE, Saeed MJ, Novak E, et al. Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality. JAMA Netw Open, 2018, 1(3): e180452.
55.	PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005, 112(3): 416-422.
56.	Enden T, Haig Y, Kl?w NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet, 2012, 379(9810): 31-38.
57.	Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med, 2017, 377(23): 2240-2252.
58.	Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol, 2020, 7(1): e40-e49.
59.	Sharifi M, Bay C, Mehdipour M, et al. Thrombus obliteration by rapid percutaneous endovenous intervention in deep venous occlusion (TORPEDO) trial: midterm results. J Endovasc Ther, 2012, 19(2): 273-280.
60.	Comerota AJ, Kearon C, Gu CS, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation, 2019, 139(9): 1162-1173.
61.	Kearon C, Gu CS, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost, 2019, 119(4): 633-644.
62.	Kahn SR, Julian JA, Kearon C, et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord, 2020, 8(1): 8-23.
63.	Galanaud JP, Sevestre MA, Pernod G, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost, 2017, 15(5): 907-916.
64.	Ferrara F, Meli F, Amato C, et al. Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. Angiology, 2006, 57(4): 418-423.
65.	Franco L, Giustozzi M, Agnelli G, et al. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost, 2017, 15(6): 1142-1154.
66.	Kirkilesis G, Kakkos SK, Bicknell C, et al. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev, 2020, 4(4): CD013422.
67.	Decousus H, Quéré I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med, 2010, 152(4): 218-224.
68.	Di Minno MN, Ambrosino P, Ambrosini F, et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost, 2016, 14(5): 964-972.
69.	Jorgensen JO, Hanel KC, Morgan AM, et al. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg, 1993, 18(1): 70-73.
70.	Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med, 2010, 363(13): 1222-1232.
71.	Cosmi B, Filippini M, Tonti D, Avruscio G, et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost, 2012, 10(6): 1026-1035.
72.	Galanaud JP, Blaise S, Sevestre MA, et al. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res, 2018, 171: 179-186.
73.	Duffett L, Kearon C, Rodger M, et al. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost, 2019, 119(3): 479-489.
74.	Lozano FS, Almazan A. Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg, 2003, 37(6): 415-420.
75.	Ageno W, Haas S, Weitz JI, et al. Upper extremity DVT versus lower extremity DVT: Perspectives from the GARFIELD-VTE registry. Thromb Haemost, 2019, 119(8): 1365-1372.
76.	Thiyagarajah K, Ellingwood L, Endres K, et al. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis. Thromb Res, 2019, 174: 34-39.
77.	Montiel SF, Ghazvinian R, Gotts?ter R, et al. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J, 2017, 15: 26.
78.	Schastlivtsev I, Lobastov K, Tsaplin S, et al. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature. Thromb Res, 2019, 181: 24-28.
79.	Guzzo JL, Chang K, Demos J, et al. Preoperative thrombolysis and venoplasty affords no benefit in patency following first rib resection and scalenectomy for subacute and chronic subclavian vein thrombosis. J Vasc Surg, 2010, 52(3): 658-662.
80.	Bosma J, Vahl AC, Coveliers HM, et al. Primary subclavian vein thrombosis and its long-term effect on quality of life. Vascular, 2011, 19(6): 327-332.
81.	傅麒寧, 吳洲鵬, 孫文彥, 等. 《輸液導管相關靜脈血栓形成中國專家共識》臨床實踐推薦. 中國普外基礎與臨床雜志, 2020, 27(4): 412-418.
82.	Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol, 2020, 7(1): e18-e27.
83.	Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e737S-e801S.
84.	Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol, 2019, 6(10): e500-e509.
85.	Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 2005, 106(2): 401-407.
86.	Harris SA, Velineni R, Davies AH. Inferior vena cava filters in pregnancy: a systematic review. J Vasc Interv Radiol, 2016, 27(3): 354-360.
87.	Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood, 2002, 100(10): 3470-3478.
88.	Posch F, K?nigsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res, 2015, 136(3): 582-589.
89.	Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med, 2018, 378(7): 615-624.
90.	Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost, 2018, 118(8): 1439-1449.
91.	Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med, 2020, 382(17): 1599-1607.
92.	Malec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus, 2020, 29(1): 37-44.
93.	Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132(13): 1365-1371.
94.	Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban versus vitamin k antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med, 2019, 171(10): 685-694.

1. Kakkos SK, Gohel M, Baekgaard N, et al. European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg, 2020: S1078-5884(20)30868-6.
2. Wanhainen A, Verzini F, Van Herzeele I, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg, 2019, 57(1): 8-93.
3. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis, 2016, 41(1): 3-14.
4. Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis, 2009, 28(4): 401-409.
5. Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest, 2016, 149(2): 315-352.
6. Cogo A, Lensing AW, Koopman MM, et al. Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ, 1998, 316(7124): 17-20.
7. Ageno W, Camporese G, Riva N, et al. Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study. Lancet Haematol, 2015, 2(11): e474-e480.
8. Karande GY, Hedgire SS, Sanchez Y, et al. Advanced imaging in acute and chronic deep vein thrombosis. Cardiovasc Diagn Ther, 2016, 6(6): 493-507.
9. Sampson FC, Goodacre SW, Thomas SM, et al. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol, 2007, 17(1): 175-181.
10. Dronkers CE, Klok FA, Huisman MV. Current and future perspectives in imaging of venous thromboembolism. J Thromb Haemost, 2016, 14(9): 1696-1710.
11. Schellong SM, Schwarz T, Halbritter K, et al. Complete compression ultrasonography of the leg veins as a single test for the diagnosis of deep vein thrombosis. Thromb Haemost, 2003, 89(2): 228-234.
12. Geersing GJ, Zuithoff NP, Kearon C, et al. Exclusion of deep vein thrombosis using the Wells rule in clinically important subgroups: individual patient data meta-analysis. BMJ, 2014, 348: g1340.
13. Kelly J, Hunt BJ. The utility of pretest probability assessment in patients with clinically suspected venous thromboembolism. J Thromb Haemost, 2003, 1(9): 1888-1896.
14. Garcia-Fuster MJ, Fabia MJ, Furio E, et al. Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord, 2014, 14: 178.
15. Zhou M, Zhang L, Ding Y, et al. Extensive screening for occult malignancy in unprovoked venous thromboembolism: A meta-analysis. Thromb Res, 2017, 157: 147-153.
16. Klein A, Shepshelovich D, Spectre G, et al. Screening for occult cancer in idiopathic venous thromboembolism—Systemic review and meta-analysis. Eur J Intern Med, 2017, 42: 74-80.
17. Kleinjan A, van Doormaal FF, Prins MH, et al. Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism. Neth J Med, 2012, 70(7): 311-317.
18. Stevens SM, Woller SC, Bauer KA, et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis, 2016, 41(1): 154-164.
19. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med, 2017, 377(12): 1177-1187.
20. Garcia-Horton A, Kovacs MJ, Abdulrehman J, et al. Impact of thrombophilia screening on venous thromboembolism management practices. Thromb Res, 2017, 149: 76-80.
21. Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis, 2015, 39(3): 367-378.
22. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med, 1996, 334(11): 677-681.
23. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med, 1996, 334(11): 682-687.
24. Othieno R, Okpo E, Forster R. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev, 2018, (3): CD003076.
25. Boutitie F, Pinede L, Schulman S, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ, 2011, 342: d3036.
26. Kearon C, Ginsberg JS, Anderson DR, et al. Comparison of1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost, 2004, 2(5): 743-749.
27. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation, 2001, 103(20): 2453-2460.
28. Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor’s choice —A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg, 2019, 57(5): 685-701.
29. Prins MH, Lensing AWA, Prandoni P, et al. Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Adv, 2018, 2(7): 788-796.
30. Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med, 2013, 368(8): 699-708.
31. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med, 2017, 376(13): 1211-1222.
32. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med, 2012, 367(21): 1979-1987.
33. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med, 2012, 366(21): 1959-1967.
34. Shaw JR, Douketis J, Le Gal G, et al. Periprocedural interruption of anticoagulation in patients with cancer-associated venous thromboembolism: An analysis of thrombotic and bleeding outcomes. J Thromb Haemost, 2019, 17(7): 1171-1178.
35. Meissner MH. Duplex follow-up of patients with DVT: does it have clinical significance? Semin Vasc Surg, 2001, 14(3): 215-221.
36. Ascher E, Depippo PS, Hingorani A, et al. Does repeat duplex ultrasound for lower extremity deep vein thrombosis influence patient management? Vasc Endovascular Surg, 2004, 38(6): 525-531.
37. Schulman S, Granqvist S, Holmstr?m M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med, 1997, 336(6): 393-398.
38. Kyrle PA. How I treat recurrent deep-vein thrombosis. Blood, 2016, 127(6): 696-702.
39. Schulman S. How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. Blood, 2017, 129(25): 3285-3293.
40. Piran S, Schulman S. Management of recurrent venous thromboembolism in patients with cancer: A review. Thromb Res, 2018, 164 Suppl 1: S172-S177.
41. Siragusa S, Malato A, Saccullo G, et al. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. Am J Hematol, 2011, 86(11): 914-917.
42. Partsch H, Bl?ttler W. Compression and walking versus bed rest in the treatment of proximal deep venous thrombosis with low molecular weight heparin. J Vasc Surg, 2000, 32(5): 861-869.
43. Roumen-Klappe EM, den Heijer M, van Rossum J, et al. Multilayer compression bandaging in the acute phase of deep-vein thrombosis has no effect on the development of the post-thrombotic syndrome. J Thromb Thrombolysis, 2009, 27(4): 400-405.
44. Arpaia G, Cimminiello C, Mastrogiacomo O, et al. Efficacy of elastic compression stockings used early or after resolution of the edema on recanalization after deep venous thrombosis: the COM. PRE Trial. Blood Coagul Fibrinolysis, 2007, 18(2): 131-137.
45. Amin EE, Bistervels IM, Meijer K, et al. Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. Blood, 2018, 132(21): 2298-2304.
46. Kahn SR, Shapiro S, Ducruet T, et al. Graduated compression stockings to treat acute leg pain associated with proximal DVT. A randomised controlled trial. Thromb Haemost, 2014, 112(6): 1137-1141.
47. Prandoni P, Lensing AW, Prins MH, et al. Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med, 2004, 141(4): 249-256.
48. Ten Cate-Hoek AJ, Amin EE, Bouman AC, et al. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol, 2018, 5(1): e25-e33.
49. Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet, 1997, 349(9054): 759-762.
50. Aschwanden M, Jeanneret C, Koller MT, et al. Effect of prolonged treatment with compression stockings to prevent post-thrombotic sequelae: a randomized controlled trial. J Vasc Surg, 2008, 47(5): 1015-1021.
51. Ten Cate-Hoek AJ, Bouman AC, Joore MA, et al. The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. BMJ Open, 2014, 4(9): e005265.
52. Mol GC, van de Ree MA, Klok FA, et al. One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial. BMJ, 2016, 353: i2691.
53. Prandoni P, Noventa F, Quintavalla R, et al. Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. Blood, 2012, 119(6): 1561-1565.
54. Turner TE, Saeed MJ, Novak E, et al. Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality. JAMA Netw Open, 2018, 1(3): e180452.
55. PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation, 2005, 112(3): 416-422.
56. Enden T, Haig Y, Kl?w NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet, 2012, 379(9810): 31-38.
57. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med, 2017, 377(23): 2240-2252.
58. Notten P, Ten Cate-Hoek AJ, Arnoldussen CWKP, et al. Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a single-blind, multicentre, randomised trial. Lancet Haematol, 2020, 7(1): e40-e49.
59. Sharifi M, Bay C, Mehdipour M, et al. Thrombus obliteration by rapid percutaneous endovenous intervention in deep venous occlusion (TORPEDO) trial: midterm results. J Endovasc Ther, 2012, 19(2): 273-280.
60. Comerota AJ, Kearon C, Gu CS, et al. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation, 2019, 139(9): 1162-1173.
61. Kearon C, Gu CS, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis in acute femoral-popliteal deep vein thrombosis: analysis from a stratified randomized trial. Thromb Haemost, 2019, 119(4): 633-644.
62. Kahn SR, Julian JA, Kearon C, et al. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord, 2020, 8(1): 8-23.
63. Galanaud JP, Sevestre MA, Pernod G, et al. Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. J Thromb Haemost, 2017, 15(5): 907-916.
64. Ferrara F, Meli F, Amato C, et al. Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. Angiology, 2006, 57(4): 418-423.
65. Franco L, Giustozzi M, Agnelli G, et al. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost, 2017, 15(6): 1142-1154.
66. Kirkilesis G, Kakkos SK, Bicknell C, et al. Treatment of distal deep vein thrombosis. Cochrane Database Syst Rev, 2020, 4(4): CD013422.
67. Decousus H, Quéré I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med, 2010, 152(4): 218-224.
68. Di Minno MN, Ambrosino P, Ambrosini F, et al. Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost, 2016, 14(5): 964-972.
69. Jorgensen JO, Hanel KC, Morgan AM, et al. The incidence of deep venous thrombosis in patients with superficial thrombophlebitis of the lower limbs. J Vasc Surg, 1993, 18(1): 70-73.
70. Decousus H, Prandoni P, Mismetti P, et al. Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med, 2010, 363(13): 1222-1232.
71. Cosmi B, Filippini M, Tonti D, Avruscio G, et al. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). J Thromb Haemost, 2012, 10(6): 1026-1035.
72. Galanaud JP, Blaise S, Sevestre MA, et al. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer. Thromb Res, 2018, 171: 179-186.
73. Duffett L, Kearon C, Rodger M, et al. Treatment of superficial vein thrombosis: a systematic review and meta-analysis. Thromb Haemost, 2019, 119(3): 479-489.
74. Lozano FS, Almazan A. Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg, 2003, 37(6): 415-420.
75. Ageno W, Haas S, Weitz JI, et al. Upper extremity DVT versus lower extremity DVT: Perspectives from the GARFIELD-VTE registry. Thromb Haemost, 2019, 119(8): 1365-1372.
76. Thiyagarajah K, Ellingwood L, Endres K, et al. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis. Thromb Res, 2019, 174: 34-39.
77. Montiel SF, Ghazvinian R, Gotts?ter R, et al. Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis. Thromb J, 2017, 15: 26.
78. Schastlivtsev I, Lobastov K, Tsaplin S, et al. Rivaroxaban in the treatment of upper extremity deep vein thrombosis: A single-center experience and review of the literature. Thromb Res, 2019, 181: 24-28.
79. Guzzo JL, Chang K, Demos J, et al. Preoperative thrombolysis and venoplasty affords no benefit in patency following first rib resection and scalenectomy for subacute and chronic subclavian vein thrombosis. J Vasc Surg, 2010, 52(3): 658-662.
80. Bosma J, Vahl AC, Coveliers HM, et al. Primary subclavian vein thrombosis and its long-term effect on quality of life. Vascular, 2011, 19(6): 327-332.
81. 傅麒寧, 吳洲鵬, 孫文彥, 等. 《輸液導管相關靜脈血栓形成中國專家共識》臨床實踐推薦. 中國普外基礎與臨床雜志, 2020, 27(4): 412-418.
82. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol, 2020, 7(1): e18-e27.
83. Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e737S-e801S.
84. Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol, 2019, 6(10): e500-e509.
85. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 2005, 106(2): 401-407.
86. Harris SA, Velineni R, Davies AH. Inferior vena cava filters in pregnancy: a systematic review. J Vasc Interv Radiol, 2016, 27(3): 354-360.
87. Bates SM, Ginsberg JS. How we manage venous thromboembolism during pregnancy. Blood, 2002, 100(10): 3470-3478.
88. Posch F, K?nigsbrügge O, Zielinski C, et al. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res, 2015, 136(3): 582-589.
89. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med, 2018, 378(7): 615-624.
90. Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: Results from the Hokusai VTE Cancer Study. Thromb Haemost, 2018, 118(8): 1439-1449.
91. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med, 2020, 382(17): 1599-1607.
92. Malec K, Broniatowska E, Undas A. Direct oral anticoagulants in patients with antiphospholipid syndrome: a cohort study. Lupus, 2020, 29(1): 37-44.
93. Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood, 2018, 132(13): 1365-1371.
94. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban versus vitamin k antagonist in antiphospholipid syndrome: A randomized noninferiority trial. Ann Intern Med, 2019, 171(10): 685-694.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

《歐洲血管外科學會（ESVS）2021 年靜脈血栓管理臨床實踐指南》解讀

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content